A Phase 1 Study Of CMC-544 Administered As A Single Agent In Subjects With B-Cell Non-Hodgkin's Lymphoma
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Incidence and severity of adverse events, dose-limiting toxicities, and changes in laboratory test results.
Pfizer CT.gov Call Center
Japan: Pharmaceuticals and Medical Devices Agency